Oncopeptides Capital Markets Day

New York, December 14, 2018

Please join Oncopeptides (ONCO-SE) executives and key opinion leaders for a discussion of Ygalo, Oncopeptides' alkylating peptide targeting multiple myeloma, and the multiple myeloma landscape including new treatments in development.

Friday, December 14th, 2018
New York City
(The event will be simultaneously webcast)
Registration and Breakfast: 8:00am - 8:30AM
Presentations 8:30am - 11:00am

Featured Speaker:

Paul Richardson, MD
Dana-Farber Cancer Institute, Clinical Program Leader & Director of Clincial Research
Jerome Lipper Multiple Myeloma Center

For more information or to RSVP, please email Alan Lada, alada@troutgroup.com or RSVP via the link below.

General Agenda

08.00 - 08.30                       Registration & Breakfast

8.30 – 09.00      Introduction to Oncopeptides including a Clinical Trials Overview
                          Jakob Lindberg, CEO of Oncopeptides

9.00 – 09.45      HORIZON and ANCHOR Trials Data Update
                          Professor Paul G Richardson, Dana-Farber Cancer Institute 

9.45 – 9.50        Short Break

09.50 – 10.10    The Evolving Myeloma Treatment Landscape and the Position of

                           Paula Boultbee, CCO at Oncopeptides 

10.10 – 10.40    Panel discussion and Q&A
                           Professor Paul G Richardson, Dana-Farber Cancer Institute
                          Jakob Lindberg, CEO of Oncopeptides
                          Christian Jacques, MD, MSc, EVP Clinical Strategy and Chief Scientific Officer
                          Paula Boultbee, CCO at Oncopeptides

10.40 – 11.00    Summary and Conclusions
                          Jakob Lindberg, CEO of Oncopeptides

RSVP for Event / Log Back in

Additional menu options can be found in the menu bar on the left or at the top.

Oncopeptides AB [ONCO:ST] SKr10,288 MM MCap
Po­ten­tial ap­pro­val for Melflufen (Yga­lo) 1Q21. First in class pep­tide-drug con­ju­gate (PDC) that tar­gets aminopep­ti­das­es and rapid­ly re­leas­es alky­lat­ing agents in­to tu­mor cells. H2H ver­sus Po­m­alyst com­plet­ed en­roll­ment Sep '20. [more in­for­ma­tion]